1. Home
  2. MAN vs URGN Comparison

MAN vs URGN Comparison

Compare MAN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ManpowerGroup

MAN

ManpowerGroup

N/A

Current Price

$46.07

Market Cap

2.5B

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$26.27

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MAN
URGN
Founded
1948
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
MAN
URGN
Price
$46.07
$26.27
Analyst Decision
Hold
Strong Buy
Analyst Count
12
7
Target Price
$51.94
★ $60.71
AVG Volume (30 Days)
911.0K
★ 1.2M
Earning Date
10-15-2026
11-04-2026
Dividend Yield
★ 3.12%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.89
N/A
Revenue
★ $17,957,100,000.00
$1,128,000.00
Revenue This Year
$6.51
$190.44
Revenue Next Year
$3.29
$69.25
P/E Ratio
$24.28
★ N/A
Revenue Growth
★ 0.58
N/A
52 Week Low
$25.15
$16.50
52 Week High
$63.88
$50.81

Technical Indicators

Market Signals
Indicator
MAN
URGN
Relative Strength Index (RSI) 44.18 29.46
Support Level $25.57 $22.61
Resistance Level $48.48 $27.76
Average True Range (ATR) 1.67 2.03
MACD 0.40 -0.45
Stochastic Oscillator 47.54 20.19

Price Performance

Historical Comparison
MAN
URGN

About MAN ManpowerGroup

ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: